# Effectiveness of Chinese herbal medicine on improving sleep and mental health in adults: Study protocol for a stepped-wedge cluster randomized trial

**Authors:** Hiu To Tang, Hoi Ki Wong, Jingyuan Luo, Jialing Zhang, Qin Liu, Lixiang Zhai, Rachel Ngan Yin Chan, Yun Kwok Wing, Shirley Xin Li, Wing Fai Yeung, Albert Yeung, Francesco Recchia, Chun Hoi Cheung, Junjun Yang, Danny J. Yu, Zhaoxiang Bian, Yujin Choi, Hiu To Tang, Arshiya Sultana

PMC · DOI: 10.12688/f1000research.163698.1 · F1000Research · 2025-06-04

## TL;DR

This study will evaluate how well Chinese herbal medicine improves sleep and mental health in adults with depression, anxiety, and insomnia.

## Contribution

It introduces a stepped-care approach using CHM in a large-scale, pragmatic trial design.

## Key findings

- The study will assess symptom severity using validated scales at multiple time points.
- Results may influence the integration of CHM into mainstream healthcare systems.
- A stepped-wedge design allows for sequential evaluation of CHM effectiveness.

## Abstract

Depression, anxiety, and insomnia significantly impact global health and impose substantial health burdens worldwide. Conventional treatments including pharmacotherapy and psychotherapy face limitations in efficacy, side effects, and accessibility. Despite preliminary evidence suggesting the potential of Chinese herbal medicine (CHM) in managing these conditions, large-scale evaluations are lacking. This study aims to examine the effectiveness of CHM for the treatment of adults experiencing mild-to-moderate symptoms of depression, anxiety, and insomnia.

This study will be a multicenter, assessor-blinded, pragmatic stepped-wedge cluster randomized trial. Districts will be randomized to receive the CHM intervention sequentially in four steps based on a computer-generated number, while control districts remain unexposed until their respective intervention phase. The intervention consists of a three-level stepped-care approach: Level 1 involves herbal tisane for mild symptoms, Level 2 offers standardized CHM for moderate symptoms or non-responders to Level 1, and Level 3 combines personalized CHM with psychotherapy for those not improved by Level 2. Symptom severity will be assessed using validated scales, Patient Health Questionnaire-9 for depression, Generalized Anxiety Disorder-7 for anxiety, and Insomnia Severity Index for insomnia, with primary outcomes measured at baseline, post-intervention, and follow-up. The study was approved by the Hong Kong Baptist University Research Ethics Committee (Approval No.: REC/22-23/0709).

This study will provide significant insights into the effectiveness of a stepped-care CHM intervention for alleviating depression, anxiety, and insomnia. The results could guide future decision-making regarding the integration of CHM into mainstream healthcare systems in Hong Kong and beyond.

Chinese Clinical Trial Registry, ChiCTR2400083685, April 30, 2024,
https://www.chictr.org.cn/hvshowprojectEN.html?id=251238&v=1.0

## Linked entities

- **Diseases:** depression (MONDO:0002050), anxiety (MONDO:0005618), insomnia (MONDO:0013600)

## Full-text entities

- **Diseases:** anxiety (MESH:D001007), Depression (MESH:D003866), Insomnia (MESH:D007319), Generalized Anxiety Disorder (MESH:C000726808)
- **Chemicals:** CHM (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12536410/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12536410/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC12536410/full.md

---
Source: https://tomesphere.com/paper/PMC12536410